SHITE! I missed, still can't find it...they also have this
--AVI BioPharma,
Inc. (Nasdaq:AVII), (Nasdaq:AVIIW), (Nasdaq:AVIIZ) today announced
completion of its preclinical development program for its proprietary
NEUGENE(R) antisense drug targeting the West Nile virus, AVI 4020.
AVI has begun formal discussions with the U.S. Food and Drug
Administration (FDA) to begin human clinical trials evaluating AVI
4020. Following these discussions, AVI expects to submit an
Investigational New Drug (IND) application and initiate a Phase I
clinical trial later this year. To this end, AVI has begun
manufacturing clinical supplies of AVI 4020 at the company's
manufacturing facility in Corvallis, Ore.
Market Data 
Markets 
AI
